Neutre
Pfizer's Q2 earnings beat estimates; $4.3B writedown impacts GAAP EPS.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Pfizer reported strong Q2 earnings, with revenue of $15.03 billion and adjusted EPS of $0.77, surpassing analyst expectations. However, a $4.3 billion noncash impairment charge related to a lung cancer trial setback resulted in a GAAP EPS loss of $0.04. The company also raised its full-year revenue guidance to $60.5–62.5 billion, while reducing its COVID-19 product revenue outlook to approximately $4 billion.
Points clés
- Pfizer's Q2 revenue and adjusted EPS exceeded analyst expectations.
- A $4.3 billion noncash impairment charge led to a GAAP EPS loss.
- Full-year revenue guidance raised to $60.5–62.5 billion; COVID-19 product revenue outlook reduced to $4 billion.
Sources
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
